NASDAQ:ICCC ImmuCell Q3 2026 Earnings Date & Estimates $10.57 +0.06 (+0.58%) As of 09:35 AM Eastern This is a fair market value price provided by Massive. Learn more. ImmuCell is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 9:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call DateNovember 13, 2026Conference Call9:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ImmuCell in Q3 2026ImmuCell is expected to post earnings of $0.05 per share on revenue of $5.40 million. In the same quarter a year earlier ImmuCell reported -$0.02 per share on revenue of $5.51 million. ImmuCell last reported on August 13, 2026, posting $0.20 per share and beating the $0.05 consensus estimate.Consensus EstimatesConsensus EPS$0.05Expected Revenue$5.40 millionPrior-Year EPS-$0.02Prior-Year Revenue$5.51 millionExpected Revenue Growth-1.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.20 (Beat by +$0.15)Last Quarter Revenue$7.19 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report ImmuCell Q3 2026 Earnings FAQ When does ImmuCell report Q3 2026 earnings? ImmuCell (NASDAQ:ICCC) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is ImmuCell's Q3 2026 earnings call? ImmuCell's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ImmuCell? Analysts expect ImmuCell to post earnings of $0.05 per share for Q3 2026. How much revenue is ImmuCell expected to report? The consensus revenue estimate for ImmuCell is $5.40 million for Q3 2026. ImmuCell Earnings HeadlinesImmuCell Q3 Preliminary Sales RiseOctober 13, 2026 | finance.yahoo.comImmuCell Reports Preliminary Q3 2026 Sales Growth Of 46%;Stock UpOctober 13, 2026 | rttnews.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.October 20 at 1:00 AM | American Alternative (Ad)Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026October 12, 2026 | marketscreener.comMImmuCell Reports Preliminary Third Quarter 2026 Sales Up 46% to $8.0 MillionOctober 12, 2026 | quiverquant.comQImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales ResultsOctober 12, 2026 | globenewswire.comSee More ImmuCell Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email. Email Address About ImmuCellImmuCell (NASDAQ:ICCC) (NASDAQ: ICCC) is a biotechnology company focused on developing and commercializing products that support the health and productivity of dairy and beef cattle. The company uses antibody-based and other biological technologies to address common livestock diseases and conditions, with an emphasis on products that can be administered conveniently on farms. ImmuCell’s primary commercial product is the First Defense line, which is designed to help protect newborn calves from bovine neonatal diarrhea, a condition associated with pathogens including rotavirus, coronavirus and Escherichia coli. The company has also developed Re-Tain, an intramammary treatment intended for use against subclinical mastitis caused by Staphylococcus aureus in lactating dairy cattle. Founded in 1987 and headquartered in Portland, Maine, ImmuCell conducts product development, manufacturing and commercialization activities in the United States. Its products are marketed to the livestock health and dairy industries, with the company’s operations primarily centered on North American cattle producers and related animal-health distribution channels.View ImmuCell ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Stock Has 2 New Reasons for Investors to Pay AttentionTesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are DivergingMarketBeat Week in Review – 10/12 - 10/16Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge? Upcoming Earnings Meta Platforms (10/21/2026)AT&T (10/21/2026)Tesla (10/21/2026)Philip Morris International (10/21/2026)Kinder Morgan (10/21/2026)CME Group (10/21/2026)Moody's (10/21/2026)Abbott Laboratories (10/21/2026)Danaher (10/21/2026)Elevance Health (10/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
